Skip to main content

Sequenom Inks Deal With TGen for Skin Cancer Genetics

NEW YORK, Aug. 31 (GenomeWeb News) - Sequenom will provide the Translational Genomics Research Institute access to its candidate gene portfolio of targets associated with and individual's predisposition for skin cancer, the company announced today.

 

Under the terms of the agreement, TGen will further validate the candidate genes against its expression databases with regard to their potential use as diagnostic markers for skin cancer risk and for the clinical prognosis of skin cancer patients. Any products resulting from the collaboration will be jointly owned and commercialized, Sequenom said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.